

## **CARIS & COMPANY CO-MANAGES US \$17MILLION PIPE FOR RESVERLOGIX CORP. (TSX: RVX)**

**SAN DIEGO, CA-** January 5, 2007- Caris & Company announced the closing of a US\$17 million institutional PIPE financing for Resverlogix Corporation (TSX:RVX). Approximately US \$17 million of senior secured convertible promissory notes due January 4, 2010 (the “Notes”) and accompanying warrants to purchase, in the aggregate, approximately 408,647 common shares of Resverlogix (the “Warrants”) were sold and issued to certain U.S institutional investors. The Notes initially have an 8% interest rate payable semi-annually in arrears and are convertible into approximately 1.63 million common shares of Resverlogix at a conversion price of CAD \$12.07 per share, subject to certain adjustments. The Notes are convertible any time at the option of the note holders or, subject to certain conditions set forth in the Notes, by Resverlogix. The Warrants have an exercise price of CAD \$15.09 per share, subject to certain adjustments. Caris & Company served as co-agent on the transaction, with Oppenheimer & Co. Inc serving as lead placement agent.

### **About Resverlogix Corp.**

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company’s primary focus is to conduct leading research, development and commercialization of novel therapeutics that address the risk of Cardiovascular Disease (CVD). Through successful research efforts, the Company has expanded its CVD platform to three programs, each addressing different targets for specific commercial markets. NexVas™ Plaque Reduction (NexVas PR) is the Company’s primary program that targets ApoA-I enhancement via novel small molecules for plaque stabilization and regression. NexVas™ Vascular Inflammation (NexVas VI) is the Company’s second CVD program, a discovery stage technology focused on molecular targets of vascular inflammation. ReVas™ the Company’s third CVD program is dedicated to the research and development of therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD, in particular restenosis. The Company has partnered ReVas™ with Medtronic Inc., a world leading medical technology company. The Company’s secondary focus is TGF-Beta Shield™, a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis, with a TGF- Beta inhibitor. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases.

### **About Caris & Company**

Established in 2002, Caris & Company is a full service investment bank that services Wall Streets institutional investment community by providing differentiated, collaborative, alpha generating ideas. Headquartered in San Diego, CA, Caris & Company has offices in New York, San Francisco, and Boston. The firms’ research product includes coverage in the following areas: Biotechnology, Medical Devices, Medical Diagnostics, Healthcare IT, Semiconductors, Semi-Cap Equipment, Storage, Internet Services, Refining, Coal, Home Furnishings, Specialty Retail, Consumer Electronics, and Action Sports Retailers.

### **Media Contact:**

Judy Jeub

[jjeub@cariscompany.com](mailto:jjeub@cariscompany.com)

858-704-0311